MA42376B1 - Dérivés d'oxopyridine substitués - Google Patents

Dérivés d'oxopyridine substitués

Info

Publication number
MA42376B1
MA42376B1 MA42376A MA42376A MA42376B1 MA 42376 B1 MA42376 B1 MA 42376B1 MA 42376 A MA42376 A MA 42376A MA 42376 A MA42376 A MA 42376A MA 42376 B1 MA42376 B1 MA 42376B1
Authority
MA
Morocco
Prior art keywords
derivatives
substituted oxopyridine
oxopyridine derivatives
substituted
cardiovascular disorders
Prior art date
Application number
MA42376A
Other languages
English (en)
Other versions
MA42376A (fr
Inventor
Dieter Lang
Adrian Tersteegen
Jens Ackerstaff
Susanne Röhrig
Alexander Hillisch
Stefan Heitmeier
Nunez Eloisa Jimenez
Daniel Meibom
Katharina Meier
Jan Stampfuss
Pascal Ellerbrock
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA42376A publication Critical patent/MA42376A/fr
Publication of MA42376B1 publication Critical patent/MA42376B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des dérivés de dérivés d'oxopyridine substitués et leurs procédés de préparation, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de troubles cardio-vasculaires, de préférence de troubles thrombotiques ou thromboemboliques, d'oedèmes, et de troubles ophtalmiques.
MA42376A 2015-07-09 2016-07-05 Dérivés d'oxopyridine substitués MA42376B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (fr) 2015-07-09 2016-07-05 Dérivés d'oxopyridine substitués

Publications (2)

Publication Number Publication Date
MA42376A MA42376A (fr) 2018-05-16
MA42376B1 true MA42376B1 (fr) 2021-04-30

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42376A MA42376B1 (fr) 2015-07-09 2016-07-05 Dérivés d'oxopyridine substitués

Country Status (39)

Country Link
US (4) US10421742B2 (fr)
EP (1) EP3319956B1 (fr)
JP (1) JP6871180B2 (fr)
KR (1) KR102596164B1 (fr)
CN (2) CN113292539B (fr)
AU (1) AU2016289746B2 (fr)
CA (1) CA2990901C (fr)
CL (1) CL2018000039A1 (fr)
CO (1) CO2018000113A2 (fr)
CR (1) CR20180017A (fr)
CU (1) CU24512B1 (fr)
CY (1) CY1123996T1 (fr)
DK (1) DK3319956T3 (fr)
DO (1) DOP2018000004A (fr)
EA (1) EA036208B1 (fr)
EC (1) ECSP18001308A (fr)
ES (1) ES2856554T3 (fr)
GE (2) GEAP201914692A (fr)
HR (1) HRP20210459T1 (fr)
HU (1) HUE053552T2 (fr)
IL (1) IL256556B (fr)
JO (1) JO3703B1 (fr)
LT (1) LT3319956T (fr)
MA (1) MA42376B1 (fr)
MX (1) MX377903B (fr)
MY (1) MY196640A (fr)
NI (1) NI201800001A (fr)
PE (1) PE20180538A1 (fr)
PH (1) PH12018500057A1 (fr)
PL (1) PL3319956T3 (fr)
RS (1) RS61584B1 (fr)
SI (1) SI3319956T1 (fr)
SV (1) SV2018005610A (fr)
TN (1) TN2018000011A1 (fr)
TW (1) TWI717367B (fr)
UA (1) UA122341C2 (fr)
UY (1) UY36780A (fr)
WO (1) WO2017005725A1 (fr)
ZA (1) ZA201800826B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197896B1 (fr) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
CA2979937A1 (fr) * 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Derives d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CA3031592A1 (fr) 2016-08-31 2018-03-08 Jiangsu Hengrui Medicine Co., Ltd. Derive d'oxopicolinamide, son procede de preparation et son utilisation pharmaceutique
SI3765452T1 (sl) 2018-03-15 2022-06-30 Bayer Aktiengesellschaft Postopek za pripravo dveh derivatov 4-(((2S)-2-(4-(5-kloro-2-(1H-1,2,3 -triazol-1-il)fenil)-5-metoksi-2-oksopiridin-1(2H)-il)butanoil)amino)- 2-fluorobenzamida
MX2020010635A (es) 2018-04-10 2020-10-28 Bayer Pharma AG Un derivado de oxopiridina sustituido.
WO2020007256A1 (fr) 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 Formes cristallines d'un dérivé d'oxypyridine amide et leur procédé de préparation
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
CA3123324A1 (fr) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Derives d'oxopyridine substitues pour le traitement et/ou la prophylaxie de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques
US20220144848A1 (en) 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
KR20210106504A (ko) 2018-12-21 2021-08-30 바이엘 악티엔게젤샤프트 치환된 옥소피리딘 유도체
US20230027295A1 (en) * 2019-09-27 2023-01-26 Shenzhen Salubris Pharmaceuticals Co., Ltd. Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
JP7700218B2 (ja) 2020-09-17 2025-06-30 浙江海正薬業股▲ふん▼有限公司 ピペラジン誘導体、その製造方法、およびその使用
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
EP4304561A1 (fr) * 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluorométhyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzénaheptaphane-74-carboxamide
WO2022189280A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
MX2023010614A (es) * 2021-03-09 2023-09-19 Bayer Ag Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida.
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (fr) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 Forme cristalline d'un dérivé d'oxopyridine substitué et son procédé de préparation
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
JP2026509613A (ja) 2023-03-31 2026-03-19 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含む医薬剤形
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
WO2024251276A1 (fr) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 Nouveau procédé de préparation d'un composé oxopyridine, intermédiaire clé et utilisation
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
AU2024309220A1 (en) 2023-06-30 2026-01-29 Shenzhen Salubris Pharmaceuticals Co., Ltd Polysubstituted macrocyclic compound, and preparation method therefor and use thereof
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
CA2428191A1 (fr) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Derives d'acide utiles comme inhibiteurs de serines proteases
EP1526131A1 (fr) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones et -pyridones et leur utilisation comme inhibiteurs de la thrombine
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2013056034A1 (fr) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia
DK2794597T3 (en) * 2011-12-21 2018-01-15 Ono Pharmaceutical Co PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
PT2880026T (pt) * 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihidropiridona p1 como inibidores de fator xia
HK1220406A1 (zh) 2013-03-14 2017-05-05 Chdi Foundation, Inc. 组蛋白去乙酰酶抑制剂及组合物
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
EP3063150B1 (fr) * 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substituée
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
CN105829298B (zh) * 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
EP3197896B1 (fr) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
WO2016046156A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046157A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia
US20170298052A1 (en) 2014-09-24 2017-10-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN108137549B (zh) * 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂

Also Published As

Publication number Publication date
HUE053552T2 (hu) 2021-07-28
CA2990901C (fr) 2024-11-12
AU2016289746A1 (en) 2018-01-25
CN108026072B (zh) 2021-08-17
HK1255045A1 (zh) 2019-08-02
WO2017005725A1 (fr) 2017-01-12
JP2018519323A (ja) 2018-07-19
CN108026072A (zh) 2018-05-11
JP6871180B2 (ja) 2021-05-12
UY36780A (es) 2017-01-31
CY1123996T1 (el) 2022-07-22
SI3319956T1 (sl) 2021-02-26
CO2018000113A2 (es) 2018-06-12
US20230024752A1 (en) 2023-01-26
UA122341C2 (uk) 2020-10-26
US20250282748A1 (en) 2025-09-11
PH12018500057A1 (en) 2018-07-09
HRP20210459T1 (hr) 2021-05-14
TN2018000011A1 (en) 2019-07-08
PE20180538A1 (es) 2018-03-20
IL256556B (en) 2021-02-28
RS61584B1 (sr) 2021-04-29
ES2856554T3 (es) 2021-09-27
PL3319956T3 (pl) 2021-07-05
ZA201800826B (en) 2021-08-25
AU2016289746B2 (en) 2020-08-20
MA42376A (fr) 2018-05-16
US11180471B2 (en) 2021-11-23
EA201890111A1 (ru) 2018-06-29
TWI717367B (zh) 2021-02-01
KR20180026761A (ko) 2018-03-13
MX377903B (es) 2025-03-10
TW201706261A (zh) 2017-02-16
US20180194745A1 (en) 2018-07-12
GEAP201914692A (en) 2019-08-12
EP3319956B1 (fr) 2021-01-06
EP3319956A1 (fr) 2018-05-16
DOP2018000004A (es) 2018-01-31
CN113292539B (zh) 2023-12-22
CN113292539A (zh) 2021-08-24
CL2018000039A1 (es) 2018-07-13
CA2990901A1 (fr) 2017-01-12
JO3703B1 (ar) 2021-01-31
BR112018000209A2 (pt) 2018-09-04
SV2018005610A (es) 2018-04-27
DK3319956T3 (da) 2021-03-29
EA036208B1 (ru) 2020-10-14
GEP20197046B (en) 2019-12-10
NZ739109A (en) 2024-09-27
LT3319956T (lt) 2021-02-10
MX2018000076A (es) 2018-02-26
IL256556A (en) 2018-02-28
CR20180017A (es) 2018-03-07
US10421742B2 (en) 2019-09-24
US20190367478A1 (en) 2019-12-05
KR102596164B1 (ko) 2023-11-01
CU24512B1 (es) 2021-05-12
MY196640A (en) 2023-04-25
CU20180001A7 (es) 2018-06-05
NI201800001A (es) 2018-10-19
ECSP18001308A (es) 2018-03-31

Similar Documents

Publication Publication Date Title
MA42376A (fr) Dérivés d'oxopyridine substitués
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
WO2019028306A3 (fr) Compositions et procédés permettant l'administration de virus adéno-associés
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA41013A (fr) Compositions comprenant des souches bactériennes
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
CR20210342A (es) Derivados de oxopiridina sustituidos
MA46235B1 (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
MA37928A1 (fr) Tri(hétéro)arylpyrazoles et leur utilisation